Article
A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
BMC cancer - 1 May 2020
Wakuda Kazushige, Yamaguchi Hiroyuki, Kenmotsu Hirotsugu, Fukuda Minoru, Takeshita Masafumi, Suetsugu Takayuki, Kirita Keisuke, Ebi Noriyuki, Hataji Osamu, Miura Satoru, Chibana Kenji, Okamoto Isamu, Yoshimura Kenichi, Nakagawa Kazuhiko, Yamamoto Nobuyuki, Sugio Kenji
Abstract excerpt
BACKGROUND: Patients with activating epidermal growth factor receptor (EGFR) mutations are highly responsive to EGFR-tyrosine kinase inhibitors (TKIs). However, it has been reported that approximately 15-30% of patients treated with EGFR-TKIs experience central nervous system (CNS) progression, and patients with EGFR mutations exhibit a higher incidence of brain metastasis than those without such mutations. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.